

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (UF BAP)
For the November 2023 Department of Defense Pharmacy and Therapeutics
Committee Meeting
January 3, 2024 at 10:00 AM Eastern Standard Time***

Virtual Meeting

- **General session starts at 10:00 AM Eastern Standard Time (Administrative meeting preceding)**

- **Roll Call**

- **Therapeutic Class Reviews**

Members of the Defense Health Agency (DHA) Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the Department of Defense (DoD) Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended complete exclusion candidates.

The DoD P&T Committee made recommendations for the following drugs/drug classes during the November 2023 meeting.

- **Drug Class Reviews**

- *Migraine Agents–Calcitonin Gene-Related Peptide (CGRP) Antagonist Prophylaxis Subclass*
- *Neurological Agents Miscellaneous–Movement Disorders*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**

- *adalimumab (Humira) biosimilars–Targeted Immunomodulatory Biologics (TIBs)*
 - *adalimumab-aacf injection (Idacio)*
 - *adalimumab-aaty injection (Yuflyma)*
 - *adalimumab-adaz injection (Hyrimoz)*
 - *adalimumab-adaz injection (unbranded biologic)*
 - *adalimumab-adbm injection (Cyltezo)*
 - *adalimumab-aqvh injection (Yusimry)*
 - *adalimumab-bwwd injection (Hadlima)*
 - *adalimumab-fkip injection (Hulio)*
 - *adalimumab-fkip injection (unbranded biologic)*

- *albuterol and budesonide metered dose inhaler (Airsupra) – Short-Acting Beta Agonists (SABAs)*
- *bexagliflozin (Brenzavvy) – Diabetes Non-Insulin: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors*
- *colchicine 0.5 mg tabs (Lodoco) – Cardiovascular Agents Miscellaneous*
- *latanoprost 0.005% ophthalmic solution (Iyuzeh) – Glaucoma Agents: Prostaglandin Analogs*
- *lotilaner 0.25% ophthalmic solution (Xdemyv) – Ophthalmic Anti-infectives*
- *molnupiravir (Lagevrio) Emergency Use Authorization – Antivirals for Coronavirus Disease (COVID-19)*
- *nalmefene nasal spray (Opvee) – Alcohol Deterrents-Narcotic Antagonists*
- *niraparib/abiraterone acetate (Akeega) – Oncological Agents*
- *nirmatrelvir/ritonavir (Paxlovid) – Antivirals for Coronavirus Disease COVID-19*
- *palvarotene (Sohonos) – Skeletal Muscle Relaxants and Combination*
- *polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride powder for oral solution with flavor-enhancing packets (Suflave) – Laxatives-Cathartics-Stool Softeners: Bowel Preparations*
- *quizartinib (Vanflyta) – Oncological Agent for Acute Myelogenous Leukemia (AML)*
- *sodium phenylbutyrate packets for oral suspension (Olpruva) – Gastrointestinal (GI) - 2 Agents*
- *somatogon-ghla injection (Ngenla) – Growth Stimulating Agents*

➤ **Re-evaluation of Nonformulary Generics**

- *Pulmonary-1 Agents*
 - *Inhaled Corticosteroids/Long-Acting Beta Agonists (ICS/LABAs)*
 - *budesonide/formoterol hydrofluoroalkane inhaler (Symbicort HFA)*
 - *Short-Acting Beta Agonists and Combinations*
 - *albuterol HFA 90 mcg (6.7 gram) inhaler (Proventil HFA)*
- *Contraceptives*

➤ **Utilization Management Pulmonary-1 Agents: PA Criteria and Tier 1 Copay Removal**

- *ICS/LABAs*
 - *fluticasone/salmeterol (Advair Diskus, Advair HFA)*

- *mometasone/formoterol (Dulera)*
 - *fluticasone/vilanterol (Breo Ellipta)*
 - *fluticasone/salmeterol respiclick (AirDuo Respiclick)*
 - *ICS*
 - *fluticasone (Flovent HFA)*
 - *fluticasone (Flovent Diskus)*
- **Utilization Management Issues**
- *PA Criteria—Updated PA Criteria for New FDA-Approved Indications*
 - *Targeted Immunomodulatory Biologics (TIBs): adalimumab-atto injection biosimilar (Amjevita)*
 - *Metabolic Agents Miscellaneous: odevixibat (Bylvay) and maralixibat (Livmarli)*
 - *Oncological Agents: dabrafenib (Tafinlar) and trametinib (Mekinist)*
 - *Oncological Agents: Breast Cancer: talazoparib (Talzenna)*
 - *PA Criteria—Updated PA Criteria for Reasons Other Than New Indications*
 - *Atypical Antipsychotics: brexpiprazole (Rexulti)*
 - *Phosphodiesterase-5 (PDE-5) Inhibitors: tadalafil (generic Cialis)*
 - *Skeletal Muscle Relaxants and Combinations: baclofen oral solution (Ozobax), baclofen oral suspension (Fleqsuvy), baclofen oral granules (Lyvispah)*
 - *Gastrointestinal-2 Agents: Chronic Idiopathic Constipation/Constipation-predominant Irritable Bowel Syndrome: linaclotide (Linzess) and lubiprostone (Amitiza)*
- **Brand Over Generic PA Authorization and Tier 1 copay**
- *Pulmonary-2 Agents: Long-Acting Muscarinic Antagonists – tiotropium handihaler (Spiriva Handihaler)*
- **Over-the-Counter (OTC) Formulary Addition**
- *Progestin-Only Contraceptives: norgestrel tablets (Opill)*
- **Considerations of Better Care, Healthier People and Smarter Spending**
- *Contraceptives Tier 1 Copay*
 - *segesterone acetate/ethinyl estradiol vaginal ring (Annovera)*
 - *medroxyprogesterone acetate (Depo-subq Provera)*

➤ **Panel Discussions**

The UF BAP members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the DoD P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.